TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women between the ages of 18 to 70~* Meet DSM-IV (Diagnostic and Statistical Manual version IV) criteria for schizophrenia or schizoaffective disorder based on SCID (Structured Clinical Interview for the DSM-IV) interview~* Overweight, as defined with a BMI of equal to or greater than 27 kg/m² and continuing weight gain in the past year above 2% of previous years total body weight~* Be on a stable dose of antipsychotic medication; i.e. at least one month with no dosage change, and two months from an antipsychotic switch; 5) Deemed to be symptomatically stable by the clinical staff in the last two months~Exclusion Criteria:~* Meet criteria for current alcohol or other substance dependence, opioid use for any reason or positive urine drug screen for opiates~* A history of dementia, mental retardation or other neurological disorder that may interfere with study ratings~* Not capable of giving informed consent for participation in this study~* Ongoing pregnancy~* Known sensitivity to naltrexone~* A medical disorder that is known to cause obesity~* Use of sibutramine, topiramate, amphetamines or over the counter weight remedies~* Impaired liver functions (greater than 3 times the upper limit of normal)~* Diagnosed with polycystic ovary syndrome~* Currently being treated with insulin~* Current use of Depo-Provera or any natural/synthetic hormone treatment known to cause significant weight gain

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone 25mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* clinically relevant mutation in the MCT8 gene, resulting in the clinical phenotype of AHDS.~Exclusion Criteria:~* Major illness or recent major surgery (within 4 weeks) unrelated to AHDS~* Patients who are participating in ongoing RCTs of therapeutic interventions (including clinical trials of investigational medicinal products);~* Known allergy to components in Triac tablets;~* Patients that have any contra-indication for Triac treatment.

- Gender: MALE
- Minimum Age: 1 Day
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- AHDS patients (Type: EXPERIMENTAL): all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac. The Triac dose will be individually titrated to the optimal dose level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants aged 2 months (42-98 days) at time of enrolment.~* Available for the entire study period and whose parent/legal guardian can be reached by telephone.~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal vaccine.~* A previous anaphylactic reaction to any vaccine or vaccine-related component.~* Contraindication to vaccination with a pneumococcal conjugate vaccine.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 13 valent pneumococcal conjugate vaccine
- 2 (Type: ACTIVE_COMPARATOR): 7 valent pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have 3 partial onset seizures in the month prior to screening.~* Subject must have 2 partial onset seizures during the 48 hour baseline phase.~* Signed Informed Consent.~* On 1-3 stable anti-epileptic drugs at screening.~Exclusion Criteria:~* Primary generalized seizures including clonic, tonic, clonic-tonic, absence, febrile seizures, and infantile spasms.~* Lennox-Gasteau, BECTS, and Dravet's syndrome.~* Status epliepticus within 1 year of screening.~* Any change in AED regimen with 7 days of screening.~* Progressive structural central nervous system (CNS) lesion or a progressive encephalopathy.~* Progressive errors of metabolism.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- Study Drug Level 1 (Type: EXPERIMENTAL): None
- Study Drug Level 2 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Male and female ambulatory outpatients being seen in a participating physicians office for routine care,~* Patients with a clinical diagnosis of COPD and already being treated with the maintenance therapy with long-acting anticholinergic (Tiotropium (Spiriva® HandiHaler® or Respimat®) at least 1 month and within product label~* Patient fluent in language of questionnaire and having the cognitive and functional abilities required to fill in the questionnaire alone~Exclusion criteria:~* Uncooperative patients as judged by the physician~* Patients with any conditions excluded as per Country specific package insert~* Patients currently enrolled in any clinical trial which requires a change in medication for their respiratory problems.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with COPD (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Constitutional delay of growth and puberty~* Age 14 years or more~* mean testicular volume 2.5 ml or more and less than 4 ml~* serum testosterone level less than 5 nM OR~as above, but serum testosterone 1 nM or more with normal DHEAS level, even if the mean testicular volume is less than 2.5 ml OR~as above, but tanner stage G2 and testosterone level less than 3 nM~Exclusion Criteria:~* Chronic diseases~* Primary or secondary hypogonadism~* Chromosomal anomalies~* Chronic medication that potentially adversely affects bone mineralization (excluding inhaled corticosteroid treatment)

- Gender: MALE
- Minimum Age: 14 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Testosterone (Type: ACTIVE_COMPARATOR): \~1mg/kg every 4 weeks for 6 months
- Letrozole (Type: ACTIVE_COMPARATOR): 2.5mg daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 12 years of age or older at time of screening~* Documented diagnosis of HAE, Type I or II~* Baseline rate of at least 1 Investigator-confirmed HAE attack per 4 weeks~* Adult subjects and caregivers of subjects under the age of 18 are willing and able to read, understand, and sign an informed consent form. Subjects age 12 to 17, whose caregiver provides informed consent, are willing and able to read, understand an dsign an assent form.~* Males and femailes who are fertile and sexually active must adhere to contraception requirements.~Exclusion Criteria:~* Concomitant diagnosis of another form of chronic, recurrent angioedema, such as acquired angioedema, idiopathic angioedema, or recurrent angioedema associated with urticaria.~* Participation in a prior DX-2930 study~* Treatment with any other investigational drug or exposure to an investigational device within 4 weeks prior screening~* Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications within 4 weeks prior to screening.~* Exposure to androgens within 2 weeks prior to entering the run-in period.~* Use of long-term prophylactic therapy for HAE within 2 weeks prior to entering the run-in period.~* Use of short-term prophylaxis for HAE within 7 days prior to entering the run-in period.~* Any of the following liver function test abnormalities: alanine aminotransferase (ALT) \> 3x upper limit of normal, or aspartate aminotransferase (AST) \> 3x upper limit of normal, or total bilirubin \> 2x upper limit of normal (unless the bilirubin elevation is a result of Gilbert's syndrome).~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DX-2930 300 mg every 2 weeks (Type: EXPERIMENTAL): 300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
- DX-2930 300 mg every 4 weeks (Type: EXPERIMENTAL): 300 mg DX-2930 administered every 4 weeks by subcutaneous injection
- DX-2930 150 mg every 4 weeks (Type: EXPERIMENTAL): 150 mg DX-2930 administered every 4 weeks by subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered every 2 weeks by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women \> 18 years~* Subjects with chronic plaque psoriasis stable for at least 3 months and moderate to severe for at least 6 months~* Subjects with Psoriasis Area and Severity Index (PASI) ≥ 12 and Body Surface Area (BSA) ≥ 10 %~* Subjects were candidates for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy~Exclusion Criteria:~* Subjects with an erythrodermic, guttate, palmar or plantar, generalized pustular form of psoriasis~* A history of chronic infection, recent serious or life-threatening infection (within six months, including herpes zoster), or any current sign or symptom that may indicate an infection (e.g. fever, cough);~* White blood cell counts less than 4000/mm\^3 or more than 20000/mm\^3~* Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis)~* Systemic Lupus~* Non respect of adequate wash out periods for treatments that might have an impact on the disease~* Any associated disease that could be impacted by the study treatment intake~* Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous injections of Placebo every 2 weeks
- Certolizumab Pegol 200 mg (Type: EXPERIMENTAL): Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter
- Certolizumab Pegol 400 mg (Type: EXPERIMENTAL): Subcutaneous injections of 400 mg every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet the following criteria to be enrolled in this study.~1. The patient is ≥18 years old at the time of informed consent.~2. The patient has a documented diagnosis of HAE type I or II. The diagnosis will be confirmed either by documented decreased C4 levels and/or immunogenic or functional C1-INH deficiency results (\<50% of normal levels) consistent with HAE types I and II or by medical history.~3. The current HAE attack must be in the cutaneous, abdominal and/or laryngeal (inclusive of laryngeal and pharyngeal) areas.~4. Cutaneous or abdominal HAE attacks must be moderate to very severe as determined by investigator global assessment at pre-treatment assessments~5. The patient must report at least 1 VAS score ≥ 30mm~6. The patient commences treatment within 6 hours of the attack becoming at least mild (laryngeal) or moderate (non-laryngeal) in severity, but not more than 12 hours after the onset of the attack.~7. Women of childbearing potential must have a negative urine pregnancy test and must use appropriate methods to prevent pregnancy during their participation in the study.~Exclusion Criteria:~Patients who meet any of the following criteria will be excluded from the study.~1. The patient has a diagnosis of angioedema other than HAE type I or II.~2. The patient has received previous treatment with icatibant.~3. The patient has participated in a clinical trial and has received treatment with another investigational medicinal product within the past 30 days.~4. The patient has received treatment with any pain medication since the onset of the current angioedema attack.~5. The patient has received replacement therapy (fresh frozen plasma \[FFP\], C1-INH products) less than 5 days (120 hours) from the onset of the current angioedema attack.~6. The patient is receiving treatment with angiotensin converting enzyme (ACE) inhibitors.~7. Evidence of coronary artery disease based on medical history or screening examination in particular unstable angina pectoris or severe coronary heart disease;~8. The patient has a serious concomitant illness or condition that, in the opinion of the Investigator, would be a contraindication for participation in the trial.~9. The patient is pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Single subcutaneous injection of matching placebo
- Icatibant (Type: EXPERIMENTAL): Single subcutaneous injection of icatibant, 30 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant in trekking to high altitude~* Agreement to sign the informed consent.~Exclusion Criteria:~* No agreement to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Acetazolamide (Type: ACTIVE_COMPARATOR): acetazolamide 125 mg BID
- Acetazolamide and Tadalafil (Type: EXPERIMENTAL): Intervention arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VA Augmentation and Switching Treatments for Improving Depression Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of single or recurrent, non-psychotic, major depressive disorder~* Currently taking a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) or mirtazapine for major depressive disorder~* Need for next-step treatment based on documented suboptimal outcome from current antidepressant treatment for major depressive episode (at least 6 weeks treatment with a QIDS-C16 \>= 16 or at least 8 weeks with a QIDS-C16 \>= 11; and at least 3 weeks at a stable optimal dose~* Age: 18 years of age or older~Exclusion Criteria:~* Prior inadequate response after an adequate treatment trial or clear cut intolerance to either of the study medications (aripiprazole or bupropion)~* Current treatment with bupropion, aripiprazole or any other antipsychotic agent~* Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, or psychosis not otherwise specified~* Current diagnosis of Dementia~* Current diagnosis of an eating disorder or a seizure disorder~* High suicide risk currently requiring acute intervention (other than outpatient treatment of depression)~* Unstable, serious medical condition or one requiring acute medical treatment, or anticipation of hospitalization for extended care~* Requiring immediate hospitalization for psychiatric disorders~* Physiologic substance dependence requiring detoxification (excluding nicotine) in the past 30 days (substance abuse is not an exclusion criteria)~* Taking any concomitant medication that contraindicates any of treatment options or augmenting agents known to have an antidepressant effect~* Concurrent or recent participation (within the last 30 days) in another conflicting clinical trial with a mental health, investigational drug, or medical device intervention~* Female - pregnant or lactating or planning to become pregnant~* Patient was not able or willing to provide informed consent; or changed mind about participating prior to randomization~* Patient was not referred to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switching: Bupropion-SR (Type: ACTIVE_COMPARATOR): Switching: Bupropion-SR
- Augmenting: Antidepressant + Bupropion-SR (Type: ACTIVE_COMPARATOR): Augmenting: Antidepressant + Bupropion-SR
- Augmenting: Antidepressant + Aripiprazole (Type: ACTIVE_COMPARATOR): Augmenting: Antidepressant + Aripiprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients who require treatment premedication with an antihistamine for hypersensitivity infusion reactions associated with an anti-CD20, such as Rituxan® (Rituximab) or Paclitaxel, in their first-cycle or re-treatment after 6 months or in patients with persistent infusion reactions while on maintenance or re-treatment.~* 18 years of age or older~Exclusion Criteria:~* Receipt of an investigational drug or device within the past 30 days.~* Patients with likelihood of developing or history of tumor lysis syndrome.(TLS): patients with auto-lyse, Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL) with bulky disease (single node 7 or more cm or 3 or more nodal sites with size 3 or more cm)~* Patients in whom an antihistamine may be contraindicated (e.g., narrow angle glaucoma, symptomatic prostatic hypertrophy).~* Patients who, in the opinion of the investigator, may not tolerate an IV injection of diphenhydramine 50 mg or cetirizine HCl 10 mg.~* Receipt of any antihistamine (H1 antagonist) within the past 2 hours regardless of the route of administration, e.g., diphenhydramine, cetirizine, loratadine, fexofenadine, levocetirizine, desloratadine. chlorpheniramine, clemastine, and doxylamine~* Receipt of an H2 antagonist within the past 4 hours, e.g., ranitidine, cimetidine, famotidine, nizatidine.~* Receipt of doxepin within the past 24 hours; doxepin is an antidepressant, but it also has antihistamine properties.~* Receipt of epinephrine (EpiPen® or any other brand) within the past 30 days.~* Has known allergy to hydroxyzine, cetirizine, or levocetirizine, or diphenhydramine.~* Pregnant or breastfeeding.~* Any condition that in the view of the investigator makes the patient unsuitable for enrollment in this study.~* Major medical or psychiatric illness, other than diagnosed cancer at the time of presentation or in the past that in the investigator's judgement they should not be enrolled in this clinical trial.~* Inability to provide informed consent.~* Patients on concomitant P-glycoprotein inhibitors; including antidepressants, antipsychotics (e.g., olanzapine), and benzodiazepines (e.g., alprazolam), as they may cause an increase in sedation.~* Receipt of drugs that cause sedation within the past 24 hours prior to administration of the study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: ACTIVE_COMPARATOR): Cetirizine HCl 10 mg/mL: a single 1 mL injection.
- Cohort B (Type: ACTIVE_COMPARATOR): Diphenhydramine 50 mg/mL: a single 1 mL injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete